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Abstract
Lung cancer remains the leading cause of cancer‐related deaths worldwide. The majority 
of NSCLC patients present with advanced stage disease. Lung cancer was once thought 
of as a low antigenicity cancer unlikely to benefit from immunotherapy, but has recently 
been found to have a high level of antigenicity. Moreover, a large body of research now 
exists to support both the safety and efficacy of immunotherapy in advanced stage 
NSCLC. The checkpoint inhibitors nivolumab, pembrolizumab, and atezolizumab are 
now approved by the U.S. Federal Drug Administration for second‐line treatment in 
advanced stage NSCLC. In addition to being efficacious, checkpoint inhibitors have a 
superior safety profile compared to previous standard of care, chemotherapy. Further 
trials are needed to investigate the checkpoint inhibitors’ role in combination treatment, 
first‐line treatment, and early stage disease.
Keywords: PD‐1, PD‐L1, checkpoint inhibitors, NSCLC, nivolumab, pembrolizumab, 
atezolizumab, mutational load, PD‐L1 expression, immunotherapy
1. Introduction
Lung cancer is the second most common cancer in both men and women; approximately 
14% of all new cancers diagnosed are lung cancer. Lung cancer is the leading cause of cancer 
death among both men and women; one in four cancer deaths in the Unites States is due to 
lung cancer and worldwide it accounts for 1.59 million deaths annually [1, 2]. The survival 
rates for nonsmall cell lung cancer (NSCLC) remain low with 49% of Stage IA patients, 14% 
of Stage IIIA, and 1% of Stage IV patients alive at 5 years. The majority of NSCLC patients 
present with advanced stage disease [3]. Despite years of research in treatment strategies for 
NSCLC, few significant improvements on outcomes with available cytotoxic chemotherapy 
have been made. In addition, a large portion of patients with advanced disease are not treated 
with aggressive cytotoxic therapy due to performance status or other comorbidities [4]. Major 
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inroads have been made for patients with targetable driver mutations who make up a minor‐
ity of NSCLC patients but for the vast majority of patients further innovative treatments are 
needed. In the last half decade, there has been an explosion of evidence demonstrating lung 
cancer's antigenicity and clinical response to immune therapy.
2. Lung cancer and the immune system
One of the primary functions of our immune system is the ability to detect and destroy abnor‐
mal cells, which includes malignant cells. In lymphoid tissue, T cells are activated by the anti‐
gen presenting cells (APCs) carrying antigen from the tumor. T cells are then activated by the 
APCs and migrate to the peripheral tissues where they search and destroy antigen‐expressing 
tumor cells. The human immune system maintains regulatory mechanisms to prevent auto‐
immunity or more specifically the immune system from attacking self.
In lymphatic tissue, expression of cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) neg‐
atively regulates the early stages of T‐cell activation by competing with the T‐cell costimula‐
tory receptor CD28 for binding with CD80 and CD86 expressed on the APC (Figure 1) [3, 5]. 
Antibody blockade of CTLA‐4 has been shown to increase antitumor immunity in clinical 
settings, and this has been well described in the melanoma therapy [6, 7].
In the peripheral tissues, the adaptive immune system is negatively regulated in part through 
binding of the programmed cell death protein 1 (PD‐1) expressed on activated T cells with the 
Figure 1. Immune system activation and inhibition in the lymphoid tissue. MHC, major histocompatibility complex; 
CTLA‐4, cytotoxic T‐lymphocyte‐associated antigen 4; TCR, T‐cell receptor.
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programmed death ligand 1 (PD‐L1) and/or programmed death ligand 2 (PD‐L2). Tumor cells 
can evade the immune response through upregulation of expression of PD‐L1, resulting in 
decreased T‐cell response and immune resistance (Figure 2). PD‐1 and PD‐L1 inhibitors can 
take the breaks off the T‐cell activity in peripheral tissues by blocking PD‐1 binding to PD‐L1.
It has been a previously accepted belief that lung tumors have a very low antigenicity and 
approaching lung cancer with immunotherapy would have little hope of causing any significant 
benefit. However, through thoughtful translational research, immunotherapy is now being seen 
as promising therapeutic agents with a significant potential to affect NSCLC. Smokers’ tumors 
are now understood to have some of the most complex and extensive genetic mutations seen in 
solid malignancies, and consequentially they have some of the highest antigenicity [8, 9].
In 2015, the benefits of checkpoint inhibition in the treatment of NSCLC went from theo‐
retical to breaking news with new agents such as pembrolizumab, nivolumab, and atezoli‐
zumab receiving breakthrough drug designation and later approval by the U.S. Federal 
Drug Administration (FDA) for treatment of advanced stage NSCLC in the second‐line set‐
ting after progression on or after platinum containing chemotherapy [10–12]. In the case of 
pembrolizumab, treatment was indicated only for patients with tumors expressing PD‐L1 
greater than 50% by the Dako assay. Nivolumab was approved without the need for PD‐L1 
testing. Here is a review of the key trials that brought immunotherapy into standard of care 
treatment for NSCLC. Summarization of key clinical trials in checkpoint inhibition is pre‐
sented in Table 1.
Figure 2. Immune system activation and inhibition in the peripheral tissue. MHC, major histocompatibility complex; 
TCR, T‐cell receptor; PD‐1, programmed cell death protein 1; PD‐L1, programmed death ligand.
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Clinical trial Phase trial Line of 
treatment
Histology Patients Treatment regimen OS (months) PFS 
(months)
Median DOR (months)
CheckMate 063 2 Third Squamous 117 Nivolumab 3 mg/kg every 2 
weeks
8.2 1.9 NR
CheckMate 017 3 Second line Squamous 272 Nivolumab 3 mg/kg every 2 
weeks
Docetaxel 75 mg/m2 every 3 
weeks
9.2
6.0
3.5
2.8
NR
8.4
CheckMate 057 3 Second line Nonsquamous 582 Nivolumab 3 mg/kg every 2 
weeks
Docetaxel 75 mg/m2 every 3 
weeks
12.2
9.4
2.3
4.2
17.6
5.6
Keynote‐001 1 First to fifth All histologies 495 Pembrolizumab efficacy 
reported for all doses
12.0 3.7 12.5
Keynote‐010 2/3 Second line All histologies 1034 Pembrolizumab 2 mg/kg 
every 3 weeks
Pembrolizumab 10 mg/kg 
every 3 weeks
Docetaxel 75 mg/m2 every 3 
weeks
10.4
12.7
8.5
5.0
5.2
4.1
NR
NR
6.0
CheckMate 012
Gettinger et al.
1 First line All histologies 52 Nivolumab 3 mg/kg every 2 
weeks
19.4 3.6 NR
CheckMate 012
Rizvi et al.
1 First line All histologies 56 Nivolumab 10 mg/kg + 
gemcitabine‐cisplatin 
(squamous)
Nivolumab 10 mg/kg 
+ pemetrexed‐cisplatin 
(nonsquamous)
Nivolumab 5 mg/kg 
+paclitaxel‐carboplatin (all 
histologies)
Nivolumab 10 mg/kg + 
paclitaxel‐carboplatin (all 
histologies)
11.6
19.2
NR
14.9
5.7
6.8
7.1
4.8
10.3
5.8
19.6
5.5
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Clinical trial Phase trial Line of 
treatment
Histology Patients Treatment regimen OS (months) PFS 
(months)
Median DOR (months)
CheckMate 012
Hellman et al.
1 First line All histologies 148 Nivolumab 3 mg/kg every 2 
weeks + Ipilimumab 1 mg/kg 
every 12 weeks
Nivolumab 3 mg/kg every 2 
weeks + Ipilimumab 1 mg/kg 
every 6 weeks
Nivolumab 3 mg/kg every 2 
weeks
n/a 8.1
3.9
3.6
NR
NR
NR
POPLAR 2 Second line All histologies 287 Atezolizumab 1200 mg every 
3 weeks
Docetaxel 75 mg/m2 every 3 
weeks
12.6
9.7
2.7
3
NR
7.8
OS, overall survival; PFS, progression‐free survival; DOR, duration of response; NR, not reached; n/a, not available.
Table 1. Summary of key checkpoint inhibitor trials efficacy data.
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3. Key trials in checkpoint inhibition therapy of NSCLC
3.1. Checkpoint inhibitor trials: pembrolizumab second line and beyond
3.1.1. Keynote‐001
Keynote‐001 was a phase I study assessing safety and efficacy of treatment with pembroli‐
zumab of advanced NSCLC [13]. The primary objectives were to investigate safety, side effect 
profile, and efficacy of pembrolizumab. Treatment‐related adverse events were 70.9% and 
grade 3 or higher severe adverse events were 9.5%. With regards to efficacy, overall response 
rate was 19.4%: 18% in previously treated patients and 24.8% in treatment naïve patients. 
There was no significant difference noted between treatment dose and dose interval. Current 
smokers had an increased response rate at 22.3% and never smokers had a 10.3% response 
rate. Median duration of response was 12.5 months and median progression‐free survival was 
3.7 months with an overall median survival of 12 months. Additionally, the study sought to 
evaluate PD‐L1 as a biomarker and evaluated tissue obtained within 6 months of treatment 
for PD‐L1 expression. They concluded that a percentage of 50% PD‐L1 tumor cell expression 
was associated with a higher response rate and longer progression‐free survival (PFS) and 
overall survival (OS).
Keynote‐001 was a phase I study that established safety and efficacy of pembrolizumab in 
heavily treated patients with NSCLC. Furthermore, it used the DAKO PD‐L1 expression 
assay with 22C3 antibody clone for patient selection to solidify this as the chosen PD‐L1 
assay [13].
3.1.2. Keynote‐010
Keynote‐010 was a randomized phase II/III study assessing pembrolizumab versus 
docetaxel in PD‐L1 positive advanced NSCLC [14]. Eligible patients had advanced NSCLC 
that had progressed despite two or more cycles of platinum doublet chemotherapy or 
appropriate tyrosine kinase inhibitor (TKI) therapy, a fresh tumor sample showing PD‐
L1 expression of at least 1% was required. The primary endpoints were overall survival 
and progression‐free survival both in the total population and in patients with PD‐L1 
expression ≥50%. Secondary endpoints were safety/toxicity, response rate, and duration 
of response.
In patients with a PD‐L1 tumor proportion score of 50% or greater, median overall survival 
was 14.9 months for pembrolizumab 2 mg/kg, 17.3 months for pembrolizumab 10 mg/kg, 
and 8.2 months for the docetaxel group. In the total population, median overall survival was 
10.4 months for pembrolizumab 2 mg/kg, 12.7 months for pembrolizumab 10 mg/kg, and 
8.5 months for the docetaxel group. Pembrolizumab demonstrated improvement in progres‐
sion‐free survival in patients with tumor proportion score of ≥50% but progression‐free sur‐
vival was not significantly different in the total population. Neither pembrolizumab dosage 
reached the median duration of response for patients with tumor proportion score of ≥50% or 
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all patients. The docetaxel group duration of response was 8 months in the tumor proportion 
score of ≥50% or all patients and 6 months in all patients.
With regards to toxicity, treatment‐related adverse events were 13% for pembrolizumab 2 mg/
kg, 16% for pembrolizumab 10 mg/kg, and 35% for docetaxel. Severe adverse events, grade 3 
or higher, were reported as 63% for pembrolizumab 2 mg/kg, 66% for pembrolizumab 10 mg/
kg, and 81% for docetaxel.
Based on these two landmark clinical trials, pembrolizumab was approved by the FDA for 
metastatic NSCLC in patients with PD‐L1 expressing tumors who have progression on plati‐
num doublet chemotherapy and tyrosine kinase inhibitor therapy for EGFR or ALK mutant 
tumors [12–14].
3.2. Checkpoint inhibitor trials: nivolumab second line and beyond
3.2.1. CheckMate 017
Previous phase I and II studies, CheckMate 003 and CheckMate 063, respectively, dem‐
onstrated both safety and efficacy of nivolumab in heavily pretreated NSCLC patients. 
CheckMate 003 defined treatment dose at 3 mg/kg every 2 weeks. CheckMate 063 demon‐
strated efficacy endpoints of OS of 8.2 months and overall response rate (ORR) of 14.5% with 
an adverse event rate of 74% with 17% grade 3–4 [15, 16].
Checkmate 017 was a phase 3, randomized, study investigating nivolumab as compared to 
docetaxel in the second‐line setting for treatment of advanced squamous cell NSCLC in 272 
patients [17]. Eligible patients had advanced squamous cell NSCLC and progression after one 
prior platinum containing regimen, prior treatment with EGFR TKI therapy was allowed. 
The primary endpoint was overall survival. Secondary endpoints were ORR, PFS, patient‐
reported outcomes, efficacy by PD‐L1 expression, and safety.
The median overall survival was 9.2 months in the nivolumab group, which is significantly 
higher compared to 6 months in the docetaxel treatment group. The ORR was 20% with 
nivolumab and 9% with docetaxel. The median duration of response was not reached in the 
nivolumab treatment group (2.9–20.5+ months) compared to the docetaxel treatment group 
8.4 months (1.4–15.2). The median PFS for nivolumab and docetaxel treatment groups was 
3.5 and 2.8 months, respectively. PD‐L1 expression in this study was neither predictive nor 
prognostic of any efficacy endpoints.
With regards to toxicity, treatment‐related adverse events were less frequent in the nivolumab 
treatment group. The nivolumab and docetaxel treatment groups demonstrated 58% and 86% 
of patients with any adverse event (AE), respectively. Furthermore, only 7% of the nivolumab 
treatment group demonstrated grade 3 or 4 events and no grade 5 events. Docetaxel had a 
55% grade 3 or 4 event rate and 2% of patients had events of grade 5. Docetaxel demonstrated 
higher rates of treatment‐related serious adverse events mainly attributable to hematologic 
toxic events and infections.
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This study demonstrated improved overall survival and safety profile with nivolumab treat‐
ment over standard of care second‐line therapy in squamous‐cell NSCLC. Additionally, PD‐
L1 expression was not found to be predictive or prognostic of any efficacy endpoints.
3.2.2. CheckMate 057
Checkmate 057 expanded on the results of checkmate 017 and evaluated nivolumab versus 
docetaxel in advanced nonsquamous NSCLC. This study was a randomized phase 3 trial spe‐
cifically looking at nivolumab versus docetaxel in the second‐line setting for nonsquamous 
histology NSCLC [18]. A total of 582 patients with advanced nonsquamous cell NSCLC, pro‐
gression after one prior platinum containing regimen, prior treatment with EGFR TKI therapy 
were enrolled. Patients were treated until disease progression or discontinuation of treat‐
ment due to toxic side effects or other reasons. The primary endpoint was overall survival. 
Secondary endpoints included safety, confirmed objective response, PFS, patient‐reported 
outcomes, and efficacy by PD‐L1 expression.
With regards to efficacy, the median overall survival was 12.2 months in the nivolumab group 
and was significantly higher compared to 9.4 months in the docetaxel treatment group. The 
ORR was 19% with nivolumab and 12% with docetaxel. The median duration of response in 
the nivolumab treatment group was 17.2 months compared to the docetaxel treatment group 
5.6 months. The median PFS was for nivolumab and docetaxel treatment groups were 2.3 and 
4.2 months, respectively.
Treatment‐related adverse events were less frequent in the nivolumab treatment group. The 
nivolumab and docetaxel treatment groups demonstrated 69% and 88% of patients with any 
AE. Furthermore, only 10% of the nivolumab treatment group demonstrated grade 3 or 4 
events compared to docetaxel, which had a 54% grade 3 or 4 event rate. Docetaxel demon‐
strated higher rates of treatment‐related serious adverse events as seen in prior study.
PD‐L1 expression demonstrated a strong predictive association between increased PD‐L1 
expression and clinical outcomes. Improved clinical outcomes was noted in this study but the 
magnitude of improvement across all efficacy endpoints was greater with tumors express‐
ing PD‐L1 compared to those who did not. Patients whose tumors expressed PD‐L1 dem‐
onstrated a nearly doubled median overall survival compared to docetaxel. Patients whose 
tumors did not demonstrate PD‐L1 expression, defined as <1%, demonstrated similar overall 
survival. This finding differed compared to Checkmate 017 where PD‐L1 expression was not 
predictive or prognostic for all comers.
This study demonstrated improved overall survival and safety profile with nivolumab treat‐
ment over standard of care second‐line therapy in nonsquamous cell NSCLC. It also found 
no significant difference in overall survival in patients whose tumors did not express PD‐L1 
although safety profile and durability of response remain compelling arguments of the use of 
checkpoint inhibitors over chemotherapy.
These two studies resulted in the FDA approving nivolumab for the treatment of NSCLC in 
both squamous and nonsquamous after progression on a platinum containing doublet and 
TKI if applicable [11]. Nivolumab's approval and indication are not contingent on PD‐L1 
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expression. This difference has greatly impacted medical oncology's use of both drugs as 
pembrolizumab requires the tissue be assessed for PD‐L1 expression with varying costs and 
the availability of testing available in addition to the wait time for testing results, whereas 
nivolumab is approved regardless of expression level.
3.3. Checkpoint inhibitor clinical trials of nivolumab first line
3.3.1. CheckMate 012: nivolumab as monotherapy in first‐line advanced NSCLC
The purpose of Checkmate 012 was to determine if in a phase I, multicohort study, there was 
clinical benefit of nivolumab as monotherapy or combined with current standard therapies in 
first‐line advanced NSCLC [19]. Eligibility criteria for this study was Stage IIIB or IV NSCLC 
of any histology who had no prior chemotherapy for advanced disease. Prior adjuvant or neo‐
adjuvant chemotherapy was allowed. Additionally, prior radiotherapy or TKI therapy was 
permitted if completed at least 2 weeks before treatment on study. Patients were treated with 
nivolumab until disease progression, discontinuation due to toxicity, withdrawal of consent, 
or loss to follow up. The primary objective of this study was to investigate safety and toler‐
ability of nivolumab monotherapy. Secondary study objectives were ORR and PFS with OS 
included as an exploratory efficacy endpoint.
The study found an ORR of 23% with four patients with ongoing complete responses. Stable 
disease was seen in 27% of patients with a median DOR was not reached, range 4.2–25.8 
months+, and 75% was achieved by the first tumor assessment at week 11. Median OS was 
19.4 months, 16.8 months for squamous and not reached for nonsquamous histology. Median 
PFS was 3.6 months. The primary endpoint was to assess safety and tolerability, and the study 
demonstrated a 71% AE rate and 19% of grade 3 and 4 with treatment‐related adverse events 
led to discontinuation in 12% of patients.
Additionally, Checkmate 012 investigated several variables for correlation with clinical 
response to include PD‐L1 expression, KRAS, and EGFR mutation status. Tumors specimens 
were evaluable in 88% of the patients for PD‐L1 expression, finding 70% of patients had 
≥1% and 30% <1%. Clinical activity was observed regardless of PD‐L1 expression across all 
expression levels although higher response rates correlated with higher expression levels. 
Confirmed ORR was 28 and 14% in tumors with ≥1% or <1%. This study did not demonstrate 
a relationship between PFS and OS and baseline PD‐L1 expression. ORRs and disease control 
rates were higher among patients with a history of smoking. Additionally, median PFS was 
longer in current smokers compared to former smokers although the study was not powered 
to assess this. Median PFS was lower for patients with EGFR‐mutant tumors vs. EGFR‐wild‐
type. In contrast, median PFS was longer in KRAS mutant tumors compared to wild‐type.
This study demonstrated good tolerance compared to standard first‐line therapy in addition to 
demonstrating promising DOR and survival. It is important to note that this trial was not ran‐
domized, had a selected patient population with good performance status, and no standard of 
care comparison arm. Of note, four patients had durable complete clinical responses which are 
unlikely in chemotherapy treatment of NSCLC. Two phase III clinical trials will further assist 
answering the question is nivolumab monotherapy superior to current standard of care or is 
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indicated first line in a select patient population? CheckMate 026, NCT02041533, is investigat‐
ing nivolumab in the first‐line setting compared to standard of care therapy, platinum doublet 
chemotherapy, in advanced NSCLC patients with PD‐L1 expressing tumors [20]. CheckMate 
227, NCT02477826, is a multiarm study comparing nivolumab vs. nivolumab+ipilimumab vs. 
standard of care therapy platinum doublet chemotherapy ± nivolumab [21].
Checkmate 012 established safety and efficacy of nivolumab monotherapy in the first‐line 
setting of NSCLC. There are ongoing clinical trials comparing nivolumab to standard of care 
and in combination.
3.3.2. CheckMate 012: nivolumab in combination with platinum‐based doublet
Another cohort of Checkpoint 012 was released studying nivolumab in combination 
with platinum‐based doublet chemotherapy for first‐line treatment of advanced NSCLC. 
Patients were assigned by histology to receive nivolumab 10 mg/kg plus gemcitabine‐cis‐
platin (squamous) or pemetrexed‐cisplatin (nonsquamous) or nivolumab 5 or 10 mg/k 
plus paclitaxel‐carboplatin (all histologies) followed by nivolumab monotherapy [22]. 
In this study, nivolumab was administered every 3 weeks to coincide with chemother‐
apy administration. Eligibility criteria included patients with newly diagnosed advanced 
NSCLC with no prior treatment. The primary objective of this study was to assess safety 
and tolerability of immunotherapy and platinum doublet chemotherapy. Secondary objec‐
tive was antitumor activity measured by PFS and ORR. A total of 56 patients were enrolled 
in this study.
For patients treated with 10 mg/kg nivolumab plus platinum based chemotherapy adverse 
events of any grade occurred at 93% and grade 3 or 4 occurred in 50%. In the overall popula‐
tion, 95% of patients experienced any grade adverse event and 45% of patients experienced 
graded 3 or 4 treatment‐related events. Median PFS time ranging from 4.8 to 7.1 months and 
median OS in the 10 mg/kg nivolumab plus platinum‐based chemotherapy ranged from 11.6 
to 19.2 but was not reached in the nivolumab 5 mg/kg plus paclitaxel/carboplatin arm. PD‐L1 
expression was able to be quantified for 79% of patients in the study, no association was found 
between PD‐L1 expression and PFS or OS. No difference in ORR or PFS was noted between 
histologies although median DOR was longer in the squamous histology subset. Median OS 
was longer with nonsquamous versus squamous NSCLC.
Treatment‐related adverse events resulted in 21% of patients discontinuing the clinical trial. 
No treatment related deaths were reported in this study.
Based on these results, it is not clear if there is an OS benefit to combination therapy of 
nivolumab plus platinum‐based chemotherapy. There was an increase in adverse events 
although no patient‐related deaths were reported with combination therapy.
3.3.3. CheckMate 012: safety and efficacy of first‐line nivolumab and ipilimumab in advanced NSCLC
CheckMate 012 recently presented an abstract at ASCO 2016 on another cohort‐investigating 
nivolumab and ipilimumab in advanced NSCLC in their phase I clinical trial [23]. This study 
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extrapolated from efficacy in nivolumab and ipilimumab combination therapy in melanoma 
and monotherapy efficacy and safety in NSCLC. The trial enrolled 148 patients with all NSCLC 
histologies and distributed patients between four cohorts varying in nivolumab and ipili‐
mumab drug dosing. Primary endpoints investigated were safety and secondary endpoints 
were ORR and PFS. Exploratory endpoints included overall survival and efficacy by tumor 
PD‐L1 expression. The primary endpoint demonstrated adverse events in 69–77% of patients 
across cohorts and 28–35% grade 3–4 toxicities. Treatment‐related adverse events resulting 
in discontinuation of therapy was reported at 10% similar to nivolumab monotherapy trials. 
Efficacy endpoints, ORR, and PFS were improved at the higher dosing of nivolumab 3 mg/kg 
compared to 1 mg/kg. Recommended dosing for further testing is nivolumab 3 mg/kg q2 
weeks and ipilimumab 1 mg/kg q6 weeks. PD‐L1 expression corresponded with higher effi‐
cacy response rates.
This data helped to establish safety of dual complimentary checkpoint inhibition although 
final publication is pending. CheckMate 227 trial, NCT02477826, will further evaluate dual 
checkpoint inhibition with nivolumab 3 mg/kg and ipilimumab 1 mg/kg compared to stan‐
dard of care therapy [21].
3.4. Checkpoint inhibitor clinical trials of pembrolizumab first line
3.4.1. KEYNOTE 024
KEYNOTE 024 was an open‐lab phase 3 randomized controlled trial investigating pembro‐
lizumab versus platinum‐based doublet chemotherapy in first‐line setting. Inclusion criteria 
included patients with stage IV NSCLC, no sensitizing EGFR mutations or ALK transloca‐
tions, no previous chemotherapy for metastatic disease, and PD‐L1 expression of 50% of 
greater. The patients were assigned either pembrolizumab 200 mg every 3 weeks for 35 cycles 
or the investigators choice of one of five platinum‐based chemotherapy regimens for 4–6 
cycles. The primary endpoint was progression‐free survival. Secondary endpoints include 
overall survival, objective response rate, and safety. A total of 305 patients were enrolled in 
this study [24].
The estimated percentage of patients alive at 6 months was 80.2% in the pembrolizumab 
group and 72.4% in the chemotherapy group. The ORR was 44.8% with pembrolizumab and 
27.8% in the chemotherapy group. The median duration of response was not reached in the 
pembrolizumab treatment group (1.9 to 14.5+ months) compared to the chemotherapy treat‐
ment group of 6.3 months (2.1–12.6). The median PFS for pembrolizumab and docetaxel treat‐
ment groups was 10.3 and 6.0 months, respectively.
The pembrolizumab and chemotherapy treatment groups demonstrated 73.4% and 90% of 
patients with any adverse event (AE), respectively. The pembrolizumab treatment group 
demonstrated 26.6% of patients with grade 3 or 4 events and no grade 5 events. The chemo‐
therapy arm had twice the incidence of grade 3, 4, or 5 events at 53.3%.
This trial was a landmark for demonstrating superiority of checkpoint inhibition therapy with 
pembrolizumab over that of standard of care platinum‐based chemotherapy. An important 
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feature is that this population was selected for patients with at least 50% PD‐L1 expression. 
Also of recurring significance, checkpoint inhibition therapy was better tolerated with less 
overall adverse events and significantly decreased severe adverse events.
3.5. Checkpoint inhibitor clinical trials with PD‐L1 inhibitors
3.5.1. POPLAR study
POPLAR was an open label phase 2 randomized controlled trial investigation of atezoli‐
zumab vs. docetaxel in 287 patients with advanced NSCLC with progression on platinum‐
based therapies [25]. Atezolizumab is currently the only approved anti‐PD‐L1 inhibitor 
approved by the U.S. FDA for the second‐line treatment of bladder cancer. It is not approved 
for the treatment of lung cancer. The primary endpoint for the POPLAR trial was overall 
survival and secondary endpoints were ORR, PFS, and DOR. Of note, in addition to testing 
PD‐L1 expression on tumor cells it also investigated PD‐L1 expression on tumor‐infiltrating 
lymphocytes.
Atezolizumab demonstrated a trend toward improvement in overall survival of 12.6 months 
compared to the 9.7 months with docetaxel. PFS was similar between groups, 2.7 months with 
atezolizumab vs. 3.0 months with docetaxel. Median DOR for atezolizumab and docetaxel 
respectively was 14.3 months compared with 7.2 months. The survival benefit with atezoli‐
zumab correlated with increasing PD‐L1 expression on tumor cells and tumor infiltrating 
cells. Survival in patients with minimal PD‐L1 expression was similar to that of the docetaxel 
treatment group.
Treatment‐related adverse events were less frequent in the atezolizumab treatment group. 
The atezolizumab and docetaxel treatment groups demonstrated 67% and 88% of patients 
with any AE. Atezolizumab treatment group demonstrated a 40% grade 3 or 4 events rate and 
docetaxel had a 53% grade 3 or 4 event rate. Docetaxel demonstrated higher rates of treat‐
ment‐related serious adverse events as previously demonstrated in PD‐1 checkpoint inhibitor 
second‐line trials.
POPLAR was the first study of a PD‐L1 checkpoint inhibitor in a randomized clinical trial 
of patients with previously treated NSCLC. Atezolizumab showed a superior overall sur‐
vival compared with docetaxel in patients with advanced NSCLC similar to those findings in 
CheckMate 017 and 057. A trend toward increased efficacy was appreciated with increased 
PD‐L1 tumor expression. Patients with the lowest PD‐L1 expression group demonstrated 
similar overall survival to the docetaxel treatment group.
At the European Society for Medical Oncology Conference held on October 2016, the OAK, 
NCT02008227, phase 3 randomized clinical trial comparing atezolizumab to docetaxel in 
locally advanced disease or metastatic NSCLC who have failed platinum therapy was pre‐
sented. OAK demonstrated increased overall survival with atezolizumab, 13.8 months, vs. 
docetaxel, 9.6 months [26]. On October 18, 2016, the FDA approved atezolizumab for the 
treatment of patients with metastatic NSCLC in the second‐line setting based on the findings 
of the POPLAR and OAK clinical trials [10].
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4. Adverse events in checkpoint inhibition
Checkpoint inhibitors confer a unique toxicity profile compared to chemotherapy as a result 
of activation of the patient's immune system. Immune‐related adverse events (irAEs) are 
a direct result of immune system's stimulation resulting in both activation against tumor 
and against self. irAEs include but are not limited to colitis, pneumonitis, hepatitis, derma‐
titis, neuropathies, nephritis, and endocrinopathies [4, 27]. Of note, these irAEs were first 
appreciated with a different checkpoint inhibitor, ipilimumab, designed to affect CTLA‐4. 
Additionally, irAEs from anti‐PD‐1 and anti‐PD‐L1 treatment occur at a lower rate than from 
anti‐CTLA‐4 [28].
Ipilimumab's side effect profile is well studied in the treatment of melanoma. Gastrointestinal 
and dermatologic immune‐mediated toxicities were the most common. Moreover, they fre‐
quently appear in predictable time courses with dermatologic toxicities typically appearing 
in the first 2 weeks of therapy and gastrointestinal manifestations emerging after week 6 of 
therapy. Endocrinopathies are typically seen after longer duration of therapy although it is 
important to note that toxicities can occur at any time and even after cessation of therapy [29].
Anti‐PD‐1 and anti‐PD‐L1 treatment as mentioned above has a superior side effect profile 
compared to CTLA‐4 inhibitions. The most common irAEs are rash, diarrhea, and coli‐
tis. These typically present at grade 1 or 2 and do not require discontinuation of therapy. 
Endocrinopathies include hypothyroidism as the most common, thyroiditis, hyperthyroid‐
ism, hypophysitis, and adrenal insufficiency [4, 13, 16]. Pneumonitis is a rare irAE but can be 
life threatening and occurs more often in lung cancer patients [3, 28].
PD‐L1 inhibition was previously theorized to result in fewer irAEs as a result of targeting 
the tumor cell ligand and sparing PD‐L2 which is more prevalent in healthy tissue, notably 
lung cells. Unfortunately, the POPLAR study did not demonstrate reduced irAE with PD‐L1 
inhibition compared to other trials that reported adverse event rates of PD‐1 inhibitors [25].
The first and foremost purpose of checkpoint inhibitors is to determine efficacy either in mono‐
therapy or in a combination regimen. One common thread in the clinical trials reviewed and 
markedly apparent in clinical trials comparing checkpoint inhibitors to docetaxel is that in sub‐
populations with the lowest rate of response to checkpoint inhibitors treatment efficacy is simi‐
lar but adverse events are reduced compared to chemotherapy as well as grade 3 or 4 severe 
adverse events (Table 2) [18]. Therefore, if in the case of CheckMate 017, CheckMate 057, and 
POPLAR, we review the results for patients with minimal PD‐L1 expression, EGFR mutants, 
and never smokers and observe similar efficacy but reduced adverse events. This argues in 
favor of checkpoint inhibition therapy secondary to its improved safety profile [17, 18, 25].
Treatment of grade 3 or 4 irAE typically requires discontinuation of therapy and systemic 
immunosuppression with high dose corticosteroids as the first‐line therapy. Immune modu‐
lators such as infliximab can be used for patients that are steroid refractory. Grade 1 and 2 
toxicities can be managed with supportive care alone and may not require discontinuation of 
checkpoint inhibition [30].
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5. PD‐L1 expression
PD‐L1 expression has been looked at extensively to identify patients who will confer benefit 
from checkpoint inhibitor therapy. Most studies to date have demonstrated increased PD‐L1 
expression as a positive prognostic indicator of response but there is substantial debate in its 
appropriateness for patient selection for therapy. In KEYNOTE 001 and KEYNOTE 010, PD‐
L1 expression was utilized as inclusion criteria for enrollment where patients demonstrating 
at least 1% expression were eligible for the trial and divided into cohorts of 1–49% expression 
and ≥50% expression [13, 14]. The FDA‐approved pembrolizumab for second‐line therapy of 
advanced NSCLC for PD‐L1 expressing patients only, defined as patients with ≥50% PD‐L1 
expression on tumor cells. In CHECKMATE 017, PD‐L1 was neither significantly prognostic 
nor predictive of efficacy although this study was not powered for this subset analysis [17]. 
In CHECKMATE 057, PD‐L1 expression was strongly correlated with ORR and predictive 
of OS [18]. POPLAR interestingly investigated both tumor cell and immune cell expression 
of PD‐L1 and found both were prognostic of response to PD‐L1 inhibition with significant 
improvement in OS with increased expression. OS in patient with TC0 and IC0 was consistent 
with that of the docetaxel treatment group (Table 3 for comparison of studies) [25].
While several studies have supported the finding of PD‐L1 as a prognostic and predictive fac‐
tor there is debate on how to use this information if at all. First, PD‐L1 expression assays have 
varied across studies to include usage of Dako 28‐8, Dako 22C3, Ventana SP142, and Ventana 
SP263 [31]. Second, the cut‐off expression percentage has varied throughout  published  trials 
Clinical trial Line of treatment Treatment All adverse  
events (AE) %
Grade 3 or 4 AE %
CheckMate 017 3 Nivolumab 3 mg/kg every 2  
weeks
Docetaxel 75 mg/m2 every 3  
weeks
58
86
7
55
CheckMate 057 3 Nivolumab 3 mg/kg every 2  
weeks
Docetaxel 75 mg/m2 every 3  
weeks
69
88
10
54
Keynote‐010 2/3 Pembrolizumab 2 mg/kg  
every 3 weeks
Pembrolizumab 10 mg/kg  
every 3 weeks
Docetaxel 75 mg/m2 every 3  
weeks
63
66
81
13*
16*
35*
POPLAR 2 Atezolizumab 1200 mg every  
3 weeks
Docetaxel 75 mg/m2 every 3  
weeks
67
88
40
53
AE, adverse events.
*Annotates data including grade 3, 4, and 5.
Table 2. Summary of adverse events in trials for checkpoint therapy in second line setting compared to docetaxel therapy.
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Clinical trial Treatment 
regimen
Phase trial Histology PD‐L1 expression PD‐L1 assay ORR
PD‐L1+ vs. PDL1‐
Overall survival
Checkmate 063 Nivolumab 2 Squamous 59% ≥ 1%
33% ≥ 5%
33% ≥ 10%
Dako 28‐8 20% vs. 13%
24% vs. 14%
24% vs. 14%
NR
Checkmate 017 Nivolumab vs. 
docetaxel
3 Squamous 47% ≥ 1%
31% ≥ 5%
27% ≥ 10%
Dako 28‐8 17% vs. 17%
21% vs. 15%
19% vs. 16%
HR 0.69 vs. 0.58
HR 0.53 vs. 0.70
HR 0.50 vs. 0.70
Checkmate 057 Nivolumab vs. 
docetaxel
3 Nonsquamous 53% ≥ 1%
41% ≥ 5%
37% ≥ 10%
Dako 28‐8 31% vs. 9%
36% vs. 10%
37% vs. 11%
HR 0.67 vs. 0.56
HR 0.54 vs. 0.75
HR 0.58 vs. 0.70
KEYNOTE‐001 Pembrolizumab 1 All 23% < 1%
38% ≥ 1% and < 50
34% ≥ 50%
Dako 22C3 10.7% vs. NR
16.5% vs. NR
45.2% vs. NR
10.4 mo vs. NR
10.6 mo vs. NR
NR vs. NR
KEYNOTE‐010 Pembrolizumab 
vs. docetaxel
1 All 43% ≥ 50% Dako 22C3 30% vs. NR 2 mg/kg: 14.9 mo vs. NR
10 mg/kg: 17.3 mo vs. NR
CheckMate 012 
Gettinger et al
Nivolumab 1 All 70% ≥ 1%
57% ≥ 5%
Dako 28‐8 28% vs. 14%
31% vs. 15%
1 yr OS: 69% vs. 70%
1 yr OS: 73% vs. 70%
CheckMate 012
Rizvi et al
Nivolumab + 
PD‐CT
1 All 52% ≥ 1% Dako 28‐8 48% vs. 43% 1 yr OS: 70% vs. 76%
20.2 mo vs. 19.2 mo
CheckMate 012
Hellman et al
Nivolumab + 
ipilimumab
1 All 77% ≥ 1%*
23% ≥ 50%*
Dako 28‐8 57% vs. 0%
86% vs. 30%
1 yr OS: 83% vs. NR
1 yr OS: 100% vs. NR
POPLAR Atezolizumab vs. 
docetaxel
2 All 32% TC‐IC 0 < 1%
68% TC‐IC 1/2/3 
≥ 1%
37% TC‐IC 2/3 ≥ 5%
16% TC3 ≥ 50% or 
IC3 ≥ 10%
Ventana SP142 NR 1.04 vs. NR
0.59 vs. NR
0.54 vs. NR
0.49 vs. NR
OS, overall survival; ORR, objective response rate; NR, not reported; PD‐1L, programmed cell death‐1 ligand; mo, month.
*Annotates reported nivolumab 3 mg/kg q2 week + ipilimumab 1 mg/kg q6 week data only.
Table 3. PD‐L1 expression and clinical benefit.
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and includes exclusion of a small proportion of responders. Finally, PD‐L1's expression is 
dynamic calling into question the reliability in its use as a biomarker if expression varies by 
time accessioned, recent treatment, and variability in expression between sites biopsied [31–33]. 
To answer some of these questions, the “Blueprint Project” was established to formulate the 
cross‐platform standards for PD‐L1 positivity [34]. Ultimately, we hope to either validate one 
assay or demonstrate consistent reliability between assays of PD‐L1 expression. As we continue 
to learn the complex symphony of the tumor microenvironment it is likely PD‐L1 expression 
will be one of many prognostic tests utilized to tailor individual treatment.
6. Genomics and predicting clinical efficacy to checkpoint inhibition
While checkpoint inhibition appears promising at this time, it confers improvement of overall 
survival in only a minority of patients. Yet, many patients that do respond to checkpoint inhibi‐
tion demonstrate durable response to therapy making patient selection and identifying predic‐
tive and prognostic factors necessary for future clinical decision‐making. Despite the numerous 
studies that have found PD‐L1 expression to correspond with disease response, PD‐L1 expres‐
sion is not without its own shortcomings with the most significant being its validity and its nega‐
tive predictive value. There is a large variability in mutation burden within tumor types ranging 
from tens to thousands of mutations. This heterogeneity is appreciated in NSCLC secondary to 
the variability within the disease compared to smokers, nonsmokers, and patients with driver 
mutations such as EGFR‐mutant [35]. In the studies reviewed here, smoking has been found to 
correspond to clinical efficacy while decreased clinical efficacy was found in checkpoint inhibi‐
tor therapy with EGFR‐mutant patients and nonsmokers [3]. Significant research is currently 
underway evaluating molecular determinants of clinical benefit to include evaluating for muta‐
tional load, mismatch‐repair deficiency, and isolating specific somatic neoepitopes [36, 37]. Rizvi 
et al. [35] found using whole‐exome sequencing of NSCLC patients treated with pembrolizumab 
that higher nonsynonymous mutation burden in tumors was associated with improved objec‐
tive response, durable clinical benefit, and PFS. In a recently published genetic analysis of clinical 
response to anti‐CTLA‐4 in melanoma tumors, evaluating neoantigens was assessed in patients 
with clinical response. They found the presence of the neoepitope signature peptides correlated 
strongly with survival. They also found a correlation with high mutational load. Although this 
was not statistically significant in their study to support clinical benefit, the mutational load seen 
in many lung cancer patients make this an interesting topic for future research [36].
7. Conclusion
Lung cancer remains the leading cause of cancer‐related mortality worldwide with the 
majority of NSCLC patients presenting with advanced stage disease. We now have robust 
literature demonstrating both efficacy and increased safety using checkpoint inhibition com‐
pared to standard of care chemotherapy in advanced stage disease. Still, immunotherapy and 
its efficacy in treatment of NSCLC as well as our understanding of how to best utilize this 
therapy remains in its infancy. We currently have data to support improved efficacy with 
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advanced stage disease with checkpoint inhibition in the first and second line. CheckMate 
026, NCT02041533, is investigating nivolumab in the first‐line setting  compared to standard 
of care therapy, platinum doublet chemotherapy, in advanced NSCLC patients with PD‐
L1 expressing tumors [20]. CheckMate 227, NCT02477826, is a multiarm study comparing 
nivolumab vs. nivolumab+ipilimumab vs. standard of care therapy platinum doublet chemo‐
therapy ± nivolumab in the first‐line setting [21]. KEYNOTE 042, NCT02220894, is an ongoing 
clinical trials investigating pembrolizumab in the first‐line setting in PD‐L1 expressing tumors 
[38, 39]. Atezolizumab is the first FDA‐approved PD‐L1 inhibitor approved in the second‐line 
setting. As more studies mature, we look to further understand checkpoint inhibition in com‐
bination therapy, the sequence of therapy, and defining the appropriate population.
An additional question which remains unanswered is the efficacy of checkpoint inhibitors in 
early stage disease. Also, which patients benefit the most from checkpoint inhibition is still 
to be determined. It is generally accepted that patients who are smokers, have squamous 
histology, high expression of PD‐L1, and a high mutational load are more likely to respond to 
checkpoint inhibition, whereas patients who are nonsmokers, EGFR‐mutant, minimal or no 
PD‐L1 expression, and low mutational load are less likely to respond to checkpoint inhibition. 
Future investigation will help delineate which of these factors can reliably predict response to 
therapy. The ability for us to define mechanisms by which tumors evade our immune system 
complemented with our ability to predict response will hold the key to successful incorpora‐
tion of immunotherapy in a wide population of patients with lung cancer.
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